

This Manual was prepared by Drs Tammy Meyers (paediatrician Wits Paediatric HIV Working Group), Brian Eley (paediatrician Red Cross Hospital), Prof. Walter Loening of the National Directorate: Child and Youth Health and members of the South African National Paediatric HIV and AIDS Consensus team, at the request of the Chief Directorate: HIV and AIDS, STIs and Tuberculosis.

Copyright © 2005 Department of Health

Published by Jacana Media

Printed by Pinetown Printers

ISBN: 1-77009-172-6

This publication is intended to support HIV and AIDS activities and may be copied and distributed as required. Distribution for remuneration is not permitted. Permission from the copyright holder is required for any changes to the format or content of this publication.

All rights reserved.

1st edition: 2005

Guidelines for the
management of
HIV-infected children



National Department of Health
South Africa 2005

CONTENTS

Section 1 Introduction	4
Guiding principles	4
Principles of medical management	4
The human immune system	5
The pathogenesis of HIV	6
Effect on the immune system	7
Modes of HIV transmission to children	8
Prognostic factors	9
Prevention of paediatric HIV-infection	9
Prevention of primary infection	10
Prevention of unintended pregnancies among HIV-infected women ...	10
PMTCT	10
Laboratory tests to establish HIV-infection of the baby	12
Section 2 Clinical features of HIV-infection	16
Opportunities for reaching children in need of HIV care and possible ART	16
Clinical staging of HIV-infection	19
Section 3 Caring for HIV-exposed children	20
HIV-exposure	20
What should be done at clinic visits?	20
Section 4 Caring for HIV-positive children	24
Health care for HIV-positive children	24
Section 5 Nutrition support	26
Infant feeding choices	26
Nutrition intervention	27
Guidelines for feeding children with symptomatic HIV-infection ...	28
Feeding problems	29
Food supplementation	31
Section 6 HIV and AIDS clinical manifestations and complications	32
General danger signs	32
Respiratory conditions	32
Gastro-intestinal conditions	47
Candidiasis (thrush)	55
Skin conditions	56

Section 7 Other conditions and opportunistic infections	62
Cryptococcal meningitis	62
Cytomegalovirus (CMV) infection	63
Disseminated infection with <i>Mycobacterium avium</i> complex (MAC)	63
Toxoplasmosis	64
HIV encephalopathy	65
Wasting syndrome	66
Malignancies	67
Section 8 Paediatric palliative care	68
Painful conditions	68
Recommendations for pain control in children	68
The ‘analgesic ladder’	69
Breakthrough pain	72
Section 9 Caring for the terminal child	74
General management	74
Supportive care	74
Indications for inpatient management	75
Home care	75
Section 10 Antiretroviral therapy (ART)	76
Introduction	76
Issues related to paediatric ART	77
Principles for ART	77
Continuity of care units	78
Function of units	79
Requirements before ART is implemented	80
Information recording	80
Goals of ART	81
Eligibility for ART	81
Treatment of mothers/caregivers/other family members	82
ARV drug choices for children	82
General comments	82
Move from first- to second-line therapy	84
Concomitant tuberculosis (TB)	85
Dosage of ART	86
Monitoring for efficacy and safety	86
Adverse reactions	88
Adherence	95

Section 11	Adherence	96
	General consideration	96
	Adherence assessment and monitoring	96
	Adherence to ART	97
Section 12	Post-exposure prophylaxis (PEP)	102
	Universal precautions	102
	Procedure for ‘sharps injury’ or other exposure	103
	Timing of prophylaxis	105
	Post-exposure prophylaxis	105
	PEP following alleged penetrative sexual abuse	106
Section 13	Legal issues	108
	Guidelines on HIV testing and treatment of orphans and vulnerable children	108
	General statement	108
	HIV testing of children	109
Section 14	Counselling	112
	Pre-test counselling	112
	Post-test counselling	113
Section 15	Disclosure to children	116
	Reasons for disclosing HIV status	116
	Guidelines for disclosing HIV status	116
	What is the right thing to say?	117
Appendices	Appendix 1: Interim revised WHO clinical staging of HIV/AIDS for infants and children	118
	Appendix 2: Paediatric pain scales	120
	Appendix 3A: ARV drugs and TMP/SMZ paediatric dosing chart for use in resource-constrained settings	124
	Appendix 3B: Paediatric ARV and co-trimoxazole dosing	128
	Appendix 4: ARVs for children – side effects and adverse events	131
	Appendix 5: Grading of adverse events	132
	Appendix 6: Guidelines for adverse drug reaction (ADR) reporting	134
	Appendix 7: Adverse drug reaction and product quality problem report form	138
	Acronyms and abbreviations	142

RESOURCES AND ACKNOWLEDGEMENTS

Resources

AIDS Helpline:	0800 012 322
Red Ribbon Resource Centre (for free booklets on ART):	(011) 880-0405
Department of Health (Cluster: HIV and AIDS, TB and STIs):	(012) 312-0121
Department of Social Development (National HIV and AIDS Co-ordinator):	(012) 312-7500

Acknowledgements

The development of these guidelines required the collaboration of experts and professionals with in-depth experience in a wide range of matters impacting on the management of HIV-infected and HIV-exposed children.

The Department of Health wishes to acknowledge and thank all the contributors to this joint effort, as well as the Clinical Care Teams of the Cluster: Maternal, Child, Women's Health and Nutrition and Cluster: HIV and AIDS.

List of contributors

Razia Bobat	Walter Loening
Mark Cotton	Eloise Malan
Ashraf Coovadia	Michelle Meiring
Hoosen Coovadia	Harry Moultrie
Mandla Duma	Helena Rabie
Tumi Funani	Anne Robertson
Liesl Gerntholz	Nigel Rollins
Ameena Goga	Paul Roux
Glenda Gray	Haroon Saloojee
Ashraf Grimwood	H Simon Schaaf
Greg Hussey	Gayle Sherman
Prakash Jeena	Vincent Thion
Stephanie Jones	Avey Violari
David Kalombo	Nomonde Xundu
Leon Levin	

INTRODUCTION

These guidelines are intended to assist health care providers in the management of children who are HIV infected and/or affected, as outlined in the Comprehensive Plan for HIV and AIDS Care, Management and Treatment. In line with the Strategic Plan for HIV and AIDS 2000–2005, prevention of HIV infection and its early identification are dealt with in detail as they are issues of fundamental importance for everyone dealing with children.

The approach adopted is that of the continuum of care, with a holistic patient focus in an integrated health system. The focus is at the primary level within the context of the District Health System being implemented throughout the country.

The dynamic nature of the HIV and AIDS field will necessitate that these guidelines be regularly reviewed and updated in order to keep the health care providers informed of advances that impact on the management of the child. This will ensure that the highest possible quality of care is provided.

It must be stressed that these guidelines should not be used to exclude any child from receiving treatment when needed.

FIGURES AND TABLES

Figure 1	HIV testing guidelines	14
Figure 2	Clinical signs of HIV-infection	17
Figure 3	Clinical signs or conditions that may suggest HIV-infection in children	18
Table 1	Routine oral Vitamin A supplementation	21
Table 2	Treatment for worms	22
Table 3	Amoxicillin	35
Table 4	Co-trimoxazole	35
Table 5	Ceftriaxone	36
Table 6	Co-trimoxazole prophylaxis	41
Table 7	Anti-tuberculosis drugs	43
Table 8	Paracetamol	70
Table 9	Paracetamol and codeine phosphate	71
Table 10	Drug choices for children	82
Table 11	Reasons to move to second-line ART in children	84
Table 12	Paediatric ARV regimens and routine monitoring during treatment	87
Table 13	Grading the severity of paediatric adverse reactions (PACTG)	89
Table 14	Correlation between adherence and virological response to HAART	99
Table 15	Assessment of exposure risk, HIV status of source and recommendations for post-exposure prophylaxis (PEP)	104
Table 16	Recommended PEP drug regimen for adults	105